308 related articles for article (PubMed ID: 27831830)
21. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
Gillmore R; Stuart S; Kirkwood A; Hameeduddin A; Woodward N; Burroughs AK; Meyer T
J Hepatol; 2011 Dec; 55(6):1309-16. PubMed ID: 21703196
[TBL] [Abstract][Full Text] [Related]
22. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
23. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA
Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565
[TBL] [Abstract][Full Text] [Related]
24. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
Kim CJ; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MJ
Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360
[TBL] [Abstract][Full Text] [Related]
25. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
26. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
28. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
29. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
30. Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres.
Carle X; Gastaud L; Salleron J; Tardy MP; Caujolle JP; Thyss A; Thariat J; Chevallier P
Bull Cancer; 2020 Dec; 107(12):1274-1283. PubMed ID: 33183739
[TBL] [Abstract][Full Text] [Related]
31. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
32. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
Ghani MA; Fereydooni A; Chen E; Letzen B; Laage-Gaupp F; Nezami N; Deng Y; Gan G; Thakur V; Lin M; Papademetris X; Schernthaner RE; Huber S; Chapiro J; Hong K; Georgiades C
Eur Radiol; 2021 Dec; 31(12):8858-8867. PubMed ID: 34061209
[TBL] [Abstract][Full Text] [Related]
33. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
34. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria.
Ghosn M; Derbel H; Kharrat R; Oubaya N; Mulé S; Chalaye J; Regnault H; Amaddeo G; Itti E; Luciani A; Kobeiter H; Tacher V
Diagn Interv Imaging; 2021 Jan; 102(1):35-44. PubMed ID: 33012693
[TBL] [Abstract][Full Text] [Related]
35. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
Riaz A; Miller FH; Kulik LM; Nikolaidis P; Yaghmai V; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Gupta R; Wang E; Baker T; Abecassis M; Benson AB; Nemcek AA; Omary R; Salem R
JAMA; 2010 Mar; 303(11):1062-9. PubMed ID: 20233824
[TBL] [Abstract][Full Text] [Related]
36. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
[TBL] [Abstract][Full Text] [Related]
37. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
38. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
[TBL] [Abstract][Full Text] [Related]
39. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
40. Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization?
Pandey A; Pandey P; Ghasabeh MA; Zarghampour M; Khoshpouri P; Ameli S; Luo Y; Kamel IR
Radiology; 2018 Dec; 289(3):843-853. PubMed ID: 30129899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
